Aptadel Therapeutics is a European preclinical-stage biotech company based in Barcelona, Spain. It focuses on the development of cancer treatments based on Aptamer technologies. Ewing Sarcoma, a rare variety of bone cancer, affecting children, is its lead indication.
Biotechnology, cancer treatments, biotech
Between €1 million-€ 2.5 million
💡 You’re a corporate or investor and looking for startups that are innovating in the same market as Aptadel Therapeutics? We’re happy to assist you with our Startup Sourcing service.